Bio

Cross border and U.S. mergers and acquisitions of private and listed companies; public offerings of U.S. listed companies on AIM; private placements of the securities of U.K. companies in the U.S. simultaneously with public offerings in the U.K.; private equity; venture capital and hedge fund investments in portfolio companies; regulation of non–U.S. investment advisers advising U.S. persons in the changed Dodd-Frank regulatory environment; U.K. banks lending to U.S. borrowers; schemes of arrangements, rights issues and tender offers of non-U.S. issuers in the U.S.; exemptions for solicitations and dissemination of research reports by non-U.S. broker dealers in the U.S.; U.S. corporate governance matters with a focus on Sarbanes-Oxley and Dodd-Frank; licensing and intellectual property matters; general corporate assistance to non-U.S. companies establishing or expanding activities in the U.S.